A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
Status:
Unknown status
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a
corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both
infusions.